Phase 2 N=475 A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention
Migraine
Primary: Change From Baseline in Mean Monthly Migraine Days at Months 4, 5 and 6 — 0.06; -1.19; -2.25; -1.83 Days — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=17 Safety and Tolerability of Intravenous Dose of MEDI-546 in Japanese Subjects With Systemic Lupus Erythematosus.
Systemic Lupus Erythematosus
Primary: Overall Summary of Adverse Events — 6; 5; 6; 1 Participants
Phase 2 N=60 Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer
Breast Cancer
Primary: Toxicity as Assessed by Number of Grade 3 or 4 Adverse Events — 0; 2 adverse events
Phase 2 N=342 Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy
CINV
Primary: Number of Participants With Delayed Phase Complete Response(CR) — 37; 13; 27; 21 Participants — p=0.004
Phase 2 N=3 Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Ovary Cancer · Cervix Cancer · Endometrium Cancer
Primary: Part 1: Number of Participants Who Experience at Least One Adverse Event (AE) — 3; 6 Participants
Phase 2 N=48 Inhaled Nitrite in Subjects With Pulmonary Hypertension
Pulmonary Hypertension · Heart Failure, Diastolic
Primary: Change in Pulmonary Vascular Resistance (PVR) — 0.77; 0.40; -0.39 Woods units — p=0.002
Phase 2 N=42 Enzalutamide in Patients With High-risk Prostate Cancer
Adenocarcinoma of the Prostate
Primary: To Evaluate the Clinical Efficacy of Enzalutamide — 31 months
Phase 2 N=256 A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
Diabetic Nephropathies
Primary: Change From Baseline in Urinary Albumin Creatinine Ratio (UACR) at Week 12 — 195.130; 182.378; 9.072; -6.539 mg/mmol — p=0.9889
Phase 2 N=52 Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis
Primary Sclerosing Cholangitis
Primary: Percentage of Participants Experiencing Treatment-Emergent Adverse Events During the Blinded Phase — 81.8; 70.0; 100.0 percentage of participants
Phase 2 N=54 Inhaled Mometasone to Reduce Painful Episodes in Patients With Sickle Cell Disease
Sickle Cell Disease
Primary: Number of Participants Who Completed Follow up — 35; 17 Participants
Phase 2 N=47 Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction
Lung Cancer · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Area Under the Curve — 271; 537; 341; 324 ng/ml x hr
Phase 2 N=24 Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma
Sarcoma
Primary: Part 1: Incidence of Dose Limiting Toxicities — 1; 4; 3 participants
Phase 2 N=16 Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer
Skin Basal Cell Carcinoma
Primary: Overall Response Rate (ORR) — 44; 29 Percentage of participants
Phase 2 N=327 Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
Metastatic gpNMB Over-expressing Triple Negative Breast Cancer
Primary: Progression Free Survival (PFS) — 2.8; 2.9 months — p=0.761
Phase 2 N=85 Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS)
Primary Progressive Multiple Sclerosis
Primary: Change in the Area Under the Curve (AUC) of the Combinatorial Weight-Adjusted Disability Score (CombiWISE) From Baseline to Treatment Phase — -0.13; -1.04 units on a…